Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Comparison of clinical and laboratory parameters of COVID-19 in diabetic patients using different glucose-lowering drugs: a retrospective study
Khafri et al., Current Research in Medical Sciences, doi:10.22088/crms.6.2.32
Khafri et al., Comparison of clinical and laboratory parameters of COVID-19 in diabetic patients using different.., Current Research in Medical Sciences, doi:10.22088/crms.6.2.32
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 157 diabetic patients in Iran reporting shorter hospitalization with metformin, however numbers in this paper are inconsistent. The counts and percentages for death in Table 1 are not possible - 11 (13.92%) for metformin could indicate that the outcome was only known for 79/100 patients, however 8 (10.25%) for the no metformin group indicates 78 patients while the total group size is 57.
Khafri et al., 31 Dec 2022, retrospective, Iran, peer-reviewed, 6 authors, study period 20 April, 2020 - 21 July, 2020.
Contact: srostami.m@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Comparison of clinical and laboratory parameters of COVID-19 in diabetic patients using different glucose-lowering drugs: a retrospective study Soraya Khafri1, Seyedeh Farzaneh Jalali2, Faezeh Mohsenipoor3, Hadi Parsian4, Masoumeh Bayani 5, Sahar Rostami-Mansoor2,4* 1.Social Determinants of Health Research Center, Health resrearch institute, Babol University of Medical Sciences, Babol, Iran. 2.Department of Laboratory Sciences, Faculty of Paramedical Sciences, Babol University of Medical Sciences, Babol, Iran 3.Student Research Committee, Babol University of Medical Sciences, Babol, Iran 4.Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 5.Infectious Diseases and Tropical Medicine Research, Center, Health Research Institute, Babol University of Medical Sciences, [ Babol, Iran Article Info ABSTRACT Article type: Research Article Background and Objective: Diabetes is a common metabolic disease that Received: 2 December 2022 Revised: 16 December 2022 Accepted: 17 December 2022 increases the risk of mortality of COVID-19. This study was done to compare the clinical characteristics and laboratory parameters of COVID-19 in diabetic patients using different glucose-lowering drugs to find out the proper predictors of disease severity. Methods: 157 diabetic patients with confirmed COVID-19 were enrolled in three groups according to the antidiabetic medications used before admission (metformin, insulin and sulfonylurea). Findings: In 157 diabetic patients, the hospitalization length in the metformin group was lower than the no metformin group while duration of hospitalization and critical form of the disease in the insulin group were higher than the no insulin group. Furthermore, the levels of blood sugar, BUN, ALT and WBC were lower in the metformin group while ALP, ALT, BUN and creatinine levels were significantly higher in insulin group. In sulfonylurea group the levels of BUN and ALT were lower compared to the no sulfonylurea group. We also found that BUN and total bilirubin were the proper parameters to predict COVID-19 severity and mortality in metformin and insulin group respectively. Conclusion: It seems that the outcomes of renal function test, bilirubin and O2 saturation are important parameters to predict COVID-19 severity in diabetic patients using different antidiabetic medications. Keywords: COVID-19, diabetes, glucose- lowering drugs, laboratory parameters. Cite this article: khafri S, et al. Comparison of clinical and laboratory parameters of COVID-19 in diabetic patients using different glucose-lowering drugs: a retrospective study. Current Research in Medical Sciences. 2022; 6(2): 32-49 © The Author(s). [ DOI: 10.22088/crms.6.2.32 ] Publisher: Babol University of Medical Sciences  Corresponding Author: Dr. Sahar Rostami-Mansoor; Address: Assistant Professor of Clinical Biochemistry, Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran Tel: +98 1132 238 284 E-mail: srostami.m@gmail.com, ORCID:0000-0003-4999-5806 COVID-19 and different glucose-lowering drugs / Khafri S, et al 33 [ DOI: 10.22088/crms.6.2.32 ] [
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit